We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Open Orphan Plc | LSE:ORPH | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.00 | 9.50 | 10.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/11/2020 11:43 | Dummy buys are all at 24.75 so definitely all buys | discojames | |
12/11/2020 11:28 | Re: The trades going though at 24.75p. Are they Buys or Sells ? | klosters65 | |
12/11/2020 10:31 | As old Warren Buffet used to say- The stock market is where the impatient give their money to the patient. | malcolmmm | |
12/11/2020 10:07 | Pierre I think he gets genuinely excited and lets slip don't think he does it deliberately. Last one he kept getting reprimanded by Sarah L. for moving about. He may have just liked being reprimanded by her for that mind you lol | pogue | |
12/11/2020 10:00 | GregB12 Nov '20 - 09:47 - 7908 of 7909 Grab it while you can mate, its a limited window, I start fading after about 30 minutes!!! :-) | m5 | |
12/11/2020 09:58 | The thing to watch for with C is when he starts mumbling. I think he gets a bit over enthusiastic and sometimes starts saying things which are price sensitive before the rns, and then quickly switches away once he realises he's probably said to much. The mumbling bits are often the giveaway to what's coming. He probably does it partly to give the long termers bit of a head start before the market gets to know. Not saying there's going to be big news this presentation - just pure guess work, there may be or there may not be. There certainly are several areas where we are expecting news at any time and probably several other things he's thinking about which we know nothing about yet. Anyhow, it's all short term noise - in a few months we'll be much higher than now, I'm very confident of that (for valid reasons, not just hope and prayers). | pierre oreilly | |
12/11/2020 09:47 | I like the way you think, m5.OO does use Amazon servers for data storage so I hope they are as secure as they say they are! | gregb | |
12/11/2020 09:43 | Cathal Friel has a track record for a RNS issued a day after he presents at any investor webinar so look for the clues tomorrow at the Investormeet.com presentation meeting and then await Monday morning 7:00am! | adorling | |
12/11/2020 09:12 | Just a small part of The World Health Organization guide lines on Challenge Studies which have been going on for many years. It is essential that challenge studies be conducted within an ethical framework in which truly informed consent is given. When conducted, human challenge studies should be undertaken with abundant forethought, caution, POST ECBS version Page 4 and oversight. The value of the information to be gained should clearly justify the risks to human subjects. Information to be gained should clearly justify the risks to human subjects. Although human challenge trials are not a required element of every vaccine development programme, there are many reasons why a developer may request to conduct with humans a “challenge-pro | malcolmmm | |
12/11/2020 09:04 | Here's one for you.............. Richard Keeling is associate director of data management at hvivo. How much could / should we read into the Head of Clinical Innovation at Amazon Web Services and a Senior Data Manager from Amazon appearing on his LinkedIn page... | m5 | |
12/11/2020 09:00 | I can see the whole thing from 7:50 but just looking at the lab shots can't tell what they are saying - thanks | lukehold | |
12/11/2020 08:56 | See there are some silly people selling ahead of another presentation | little minx | |
12/11/2020 08:54 | Luke, the vid only plays for a while for me, then restarts. Got to the bit where she says we want to inject our young with the covid virus - so it looks like they miss the major point that it isn't the covid virus but a safe derivative of it. Quite a crucial difference. Challenge studies are illegal in much of the world, they have moral, ethical and even religious objections (an extra barrier to entry), good to see the UK seeing the major benefit of them and leading the world for once. | pierre oreilly | |
12/11/2020 08:18 | https://www.rts.ch/p | lukehold | |
12/11/2020 08:15 | They are after shares, going blue again in 15 mins... | lukehold | |
12/11/2020 08:11 | Cheers for sharing Trader 3 | sh0wmethemoney | |
12/11/2020 07:40 | UK Gov Kate Bingham – Covid CHIMs will rapidly accelerate the next wave of vaccines Science and Technology Committee Health and Social Care Committee “We have put in place standardised immune assays, so that we can compare vaccines head to head. We have created, a world first, a human challenge model for Covid vaccines. Subject to final ethics approvals—all sorts of things have to work—we should be in a position to start evaluating new vaccines in a much more streamlined, rapid way next year, which will accelerate the development of the next wave of vaccines.” Utilising Covid CHIM’s in: testing covid vaccines head to head; evaluating new vaccines; developing better vaccines; testing post Phase 3 vaccines: checking vaccine efficacy and transmission immunity etc. Coupled with the comments from Prof Van Tam & others, here is more evidence (if needed), on the UK Gov’s investment & future commitment to Covid CHIM’s. With large pharma companies now queuing up to get access to ORPH’s services, the future significant revenues (in the short to long term), are looking extremely strong. IMHO | trader_3 | |
12/11/2020 07:38 | Covid CHIM Podcast with UK Gov Kate Bingham & hVIVO’s Dr Andrew Catchpole What are “human challenge” trials, and how might they help in efforts to develop a vaccine against COVID-19? Neil McNeil talks to Kate Bingham, chair of the UK Vaccine Task Force; Peter Openshaw, Professor of Experimental Medicine at Imperial College London, Dr. Andrew Catchpole, Chief Scientific Officer at hVIVO, and Sean Cousins, a volunteer participant in several human challenge trials. hxxps://thevaccinepo Unfortunately, the producers have put the wrong recording on the link but hopefully will update it soon. Based on the podcast description, it’s great to see that the head of the UK Vaccine Task Force, is promoting Covid CHIM’s & hVIVO. | trader_3 | |
11/11/2020 23:57 | Perfect fit, 15 years working on biondvax for it to fail in Phase 3. Exactly the reason CF has put himself in the testing and not development | lukehold | |
11/11/2020 23:45 | Reversal of imutex into biondvax would be good. Exactly c's expertise. All that univ flu drug testing expertise going begging. Keep them working for mankind instead of throwing them on the dole. | pierre oreilly | |
11/11/2020 23:38 | Great stuff. If this rises tomorrow I can see the panic sellers and momentum traders jumping back in at any price . fear and greed, human nature. | malcolmmm | |
11/11/2020 23:22 | Can't believe it's almost Christmas, my neighbour has his tree up! Let's hope CF has already done his Christmas shopping before lock down. A nice imutex dividend being sliced and wrapped.This page sums it up nicely, contact Cathal Frielhttps://imutex. | lukehold |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions